Corin’s Apollo Surgical Robotics Platform Gains FDA Nod

Corin Group has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Apollo robotic-assisted surgical platform and ApolloKnee software application.
 
Corin said the Apollo platform technology will expand the company’s capabilities into further clinical applications across joint arthroplasty in the next few years. The company seeks to enhance total joint replacement patient satisfaction via objective planning, precise implantation, and data-driven continuous learning.
 
The company’s experience in robotic-assisted total knee arthroplasty (TKA) began with its OMNIBotics technology, which Corin said has gained notoriety because of its surgical precision, efficiency, and pivotal role in defining dynamic joint balance. The Apollo platform, which features the company’s BalanceBot technology, build on a decade of clinical success to further improve patient outcomes and offer a more intuitive surgeon experience.
 
ApolloKnee’s pre-resection robotic knee balancing helps to achieve personalized dynamic balance, Corin says. Gesture-controlled workflow helps increase control and efficiency, and the platform touts autonomous planning for any alignment preference.
 
An advanced cutting system works for both femoral and tibial cuts, and the platform’s compact design touts multi-application capabilities.
 
Corin’s global franchise lead Dr. Jim Pierrepont told the press, “The Apollo platform is the result of combining objective planning, precise implementation, and continuous learning in pursuit of the forgotten total joint replacement. The Apollo platform goes beyond personalized alignment of the knee during surgery. Corin’s proprietary BalanceBot technology is the world’s first, and only, system that can achieve personalized dynamic balance for each and every patient, every time.”